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Abstract
Background: Genetic polymorphisms of the TCF7L2 gene are strongly associated with large
increments in type 2 diabetes risk in different populations worldwide. In this study, we aimed to
confirm the effect of the TCF7L2 polymorphism rs7903146 on diabetes risk in a Brazilian population
and to assess the use of this genetic marker in improving diabetes risk prediction in the general
population.
Methods: We genotyped the single nucleotide polymorphisms (SNP) rs7903146 of the TCF7L2
gene in 560 patients with known coronary disease enrolled in the MASS II (Medicine, Angioplasty,
or Surgery Study) Trial and in 1,449 residents of Vitoria, in Southeast Brazil. The associations of
this gene variant to diabetes risk and metabolic characteristics in these two different populations
were analyzed. To access the potential benefit of using this marker for diabetes risk prediction in
the general population we analyzed the impact of this genetic variant on a validated diabetes risk
prediction tool based on clinical characteristics developed for the Brazilian general population.
Results: SNP rs7903146 of the TCF7L2 gene was significantly associated with type 2 diabetes in the
MASS-II population (OR = 1.57 per T allele, p = 0.0032), confirming, in the Brazilian population,
previous reports of the literature. Addition of this polymorphism to an established clinical risk
prediction score did not increased model accuracy (both area under ROC curve equal to 0.776).
Conclusion: TCF7L2 rs7903146 T allele is associated with a 1.57 increased risk for type 2 diabetes
in a Brazilian cohort of patients with known coronary heart disease. However, the inclusion of this
polymorphism in a risk prediction tool developed for the general population resulted in no
improvement of performance. This is the first study, to our knowledge, that has confirmed this
recent association in a South American population and adds to the great consistency of this finding
in studies around the world. Finally, confirming the biological association of a genetic marker does
not guarantee improvement on already established screening tools based solely on demographic
variables.
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Type 2 diabetes mellitus (T2D) is a heterogeneous disease
characterized by different degrees of insulin resistance and
defects in insulin secretion, both of which are thought to
result from the interplay of genetic and environmental
factors. The identification of causative genes that predis-
pose to T2D could provide clues to better understand the
primary pathogenesis and therefore result in better pre-
vention, diagnosis and treatment of this increasingly prev-
alent and costly condition. Up until recently, results of
research on the genetic field have been mostly elusive.
Genome-wide linkage scans have discovered chromo-
somic regions containing type 2 diabetes (T2D) suscepti-
bility genes in chromosome 10q, which were later
ascribed to intronic variations in the transcription factor
7-like 2 (TCF7L2) gene, which were strongly associated
with a twofold increase in risk for T2D in an Icelandic
population [1]. Two additional cohorts showed similar
associations, giving a combined odds ratio (OR) of 1.6
(95% confidence interval (CI) 1.4 to 1.7, p = 4.7 × 10-18
per allele). This finding has readily been replicated in
cohorts of European [1-13], Asian [6,14-16] and African
[6,17] descent, showing very similar results. Most evi-
dence for TCF7L2 has come from case-control studies or
intervention trials. There are much fewer studies that ana-
lyzed the effect of this polymorphism in the general pop-
ulation [10,18], but they suggest that diabetic carriers of
the at-risk allele have more severe β-cell dysfunction and
more microvascular complications but less metabolic syn-
drome features and a more protective lipid profile than
non-carriers.
In addition, it is necessary to confirm this association in
different populations worldwide. At moment, there are no
studies in South American populations. Therefore, this
study had two objectives: 1) investigate whether TCF7L2
variants are associated with diabetes in the Brazilian pop-
ulation; 2) evaluate how significant is the impact of this
association in predicting the prevalent diabetes risk in the
general population from Brazil.
Methods
To respond the first objective, we used a cohort of patients
from the MASS- II study and to address the second one, we
used a sample representative from the general urban pop-
ulation of the city of Vitoria, Brazil, both of which are
described below.
Multi-vessel coronary artery disease patients (MASS II 
Study)
Six-hundred and eleven patients that have documented
multi-vessel coronary artery disease and normal left ven-
tricular function were included in the MASS II trial [19].
Here we have solely used information from the baseline
characteristics of the studied population. Diabetes was
not necessary for enrollment in this protocol. From these
individuals we were able to obtain genotype data for
TCF7L2 on 560 patients, of whom 190 had diabetes mel-
litus, based on American Diabetes Association criteria or
previous treatment for diabetes. All patients gave written
informed consent for participating in the study. The Ethics
Committee of the Heart Institute approved the trial, and
all procedures were performed in accordance with the
Helsinki Declaration.
General population of Vitoria/ES, Brazil
A cross-sectional study of risk factors for cardiovascular
diseases was performed in the urban population of Vito-
ria, Brazil, using the WHO-MONICA project guidelines.
The study design was based on cross-sectional research
methodology and was developed by means of surveying
and analyzing socioeconomic and health data in a proba-
bilistic sample of residents aged 25 to 64 years from the
municipality of Vitoria, ES, Brazil. The population was
randomized and the sample was socioeconomically, geo-
graphically and demographically representative of the res-
idents of this municipality. A selection of 2,268
residential homes located in Vitoria was made and these
were visited. The project received approval from the Ethics
Committee of the Biomedical Center of Universidade Fed-
eral do Espírito Santo (UFES). The selected individuals
were asked to attend the Cardiovascular Investigation
Clinic of the University Hospital for tests to be performed
on the following day. Of the total sample, 1,577 individ-
uals attended. Participants were submitted to physical
examination. Major cardiovascular risk factors such as
smoking habits, alcohol intake, sedentarism, diabetes and
hypertension were inquired. Blood glucose, total choles-
terol, lipoprotein fractions, and triglycerides were assayed
by standard techniques in a 12 hour fasting blood sample.
Body mass index (BMI) (weight in Kg/height in meters2)
was calculated, overweight defined as a BMI ≥ 25 Kg/m2,
and obesity defined as a BMI ≥ 30 Kg/m2.
In order to screen individuals at higher risk for type 2 dia-
betes from the general population to be further investi-
gated, we previously built a prediction model of diabetes
risk in this same population (Sousa, AGP, personal com-
munication). This simple risk score model was developed
based in a population of 1,224 individuals from the gen-
eral population without known diabetes aged 35 years or
more. Also in this analysis, diabetes diagnosis was based
on fasting glycemia equal or above 126 mg/dl (7 mmol/
l). This model was externally validated in an independent
population from a different city ascertained through a
similar epidemiological protocol and items independ-
ently and significantly associated with diabetes, and cho-
sen for inclusion in the model, were age, BMI and knownPage 2 of 8
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BMI and hypertension.
The association between rs7903146 genotype and diabe-
tes was measured using a genotype trend genetic model
for an additive allelic effect captured by a regression
model for diabetes in both population.
For model construction and performance measurement,
univariate analyses were performed by logistic regression
with T2DM (FPG > 126 mg/dl) as the dependent variable.
Logistic regression coefficients were used to estimate odds
ratios for each of the independent variables in the model.
The continuous variables were categorized into strata. To
create the final model, a score was calculated by multiply-
ing the regression coefficient by 10 and rounding to the
nearest integer. Finally, a sum score was calculated for
each participant by adding the score for each significant
variable in the risk model. Sensitivity, specificity, positive
and negative predictive values and accuracy were com-
pared for different score cutoffs. In addition, the propor-
tion of subjects that needed subsequent testing (those
individuals who have score values above the cutoff value)
was compared between these several groups. In order to
evaluate the model performance, a receiver operating
characteristic (ROC) curve was built to plot probabilities
saved with the logistic regression procedure and the area
under ROC curve (AUC) was used to measure the power
to discriminate high-risk from low-risk individuals.
Genotyping of the rs7903146 polymorphism
Genomic DNA was extracted from peripheral blood leu-
kocytes by means of a salting-out procedure. PCR primers
used were: 5' ACA ATT AGA GAG CTA AGC ACT TTT TAG
GTA 3' and 5' GTG AAG TGC CCA AGC TTC TC 3'. Briefly,
the studied polymorphism was detected by polymerase
chain reaction-restriction fragment length polymorphism
assay (PCR-RFLP). A 30-cycle PCR was carried out in a
PTC-DNA Engine Tetrad2 using a 10 μL reactive solution
containing 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 2.5
mM MgCl2, 100 μM of each dNTP, 0.3U Easy Taq DNA
Polymerase, 5 pmol of each primer and 1 μL of genomic
DNA template. PCR products were digested with 1U of
RsaI restriction enzyme and visualized by 3% agarose gel
electrophoresis. The quality control for these assays was
assessed by randomly selecting 40 samples that were re-
genotyped by an independent technician. Observed con-
cordance between genotyping assays was 100%.
Statistical Analysis
We used SPSS v.13 program for statistical analysis. The
goodness of fit for normal distribution was evaluated
using the Kolmogorov-Smirnov test. To test for differences
in various characteristics, non-parametric tests were used
for continuous variables and the χ2 test and Fischer exact
test were used for categorical variables. Hardy-Weinberg
equilibrium was studied through the use of Haploview
software. For power calculation, we used the PS: Power
and Sample Size Calculation from the Department of
Biostatistics of Vanderbilt University, available for down-
load at http://biostat.mc.vanderbilt.edu/twiki/pub/Main/
PowerSampleSize/pssetup.exe. All statistical significance
tests calculates are performed as a two-sided test and a
value less than 0.05 was considered significant.
Results
In the MASS-II population, a total of 560 individuals were
genotyped for TCF7L2 gene variant rs7903146 and the
genotypic distribution for this variant was in Hardy-Wein-
berg equilibrium. There was male sex preponderance
(69.1%) and a high T2D prevalence of 31.0%. Mean BMI
was 27.1 kg/m2. According to the used weight classifica-
tion, 66.2% of this population was overweight or obese
(Table 1). The relative frequency of genotypes CC, CT and
TT in MASS II population was respectively 28,4%, 60,0%
and 11,6% (number of individuals equal to 159, 336 and
65, respectively). Allele and genotype frequencies were
not in Hardy-Weinberg equilibrium (p = 0,0004) (proba-
bly because of the high a priori chance of diabetic individ-
uals in this sample with multi-vessel coronary artery
disease). The rate of diabetes increased with an increasing
dose of allele T of rs7903146 (OR = 1.57, 95%CI 1.16–
2.11, p = 0.0032). These data are summarized in Table 3.
After adjusting for other covariates potentially associated
with T2D risk, presence of allele T was still significantly
associated with a 1.61 (95%CI 1.18–2.19) increased risk
of presenting T2D (p = 0.0025) (Table 4).
In regards to the general population of Vitoria, 1,440 sam-
ples of DNA were available and genotyped for TCF7L2
rs7903146 variant. The characteristics of this population
are shown in Table 2. Their mean age was 44.8 years
(range 23–65). The prevalence of T2D was only 7.9%.
Obesity was present in 19.3% of patients, but 55.3% were
on the overweight category (BMI ≥ 25 kg/m2). Mean BMI
was 26.2 ± 4.9 kg/m2. Non-diabetics individuals had a
lower mean BMI (25.9 versus 30.6 kg/m2 in diabetics).
The prevalence of genotype CC was 43,4% (n = 614), gen-
otype CT equal to 46,6% (n = 660) and overall prevalence
of TCF7L2 genotype TT was 10,0% (n = 142). Allele and
genotype frequencies were in Hardy-Weinberg equilib-
rium (p = 0,07) in this sample from the general popula-
tion. A slightly higher genotype prevalence was observed
in the diabetic sub-population of individuals (12.1%) as
compared to non-diabetic individuals (9.9%), but this
difference was not statistically significant (p = 0.46). Of
particular interest, the total number of diabetics that car-
ried the TT genotype, despite the relatively large size of the
initial sample, came down to only 14 people. Therefore,
the statistical power of detecting this association in thePage 3 of 8
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Table 1: Characteristics of the MASS-II population
Total rs7903146 p value
CC/CT TT
Number of patients (%) 611 (100) 495 (88.4) 65 (11.6)
Male 423 (69.1) 339 (88.5) 155 (88.1) .88
Age (years) 59.8 ± 9.1 59.7 ± 9.12 58.8 ± 9.6 .45
Mean BMI (kg/m2) 27.1 ± 4.2 27.1 ± 4.2 27.1 ± 4.2 .97
< 25 201 (33.0) 160 (32.5) 19 (29.7) .64
25 – 29.9 276 (45.4) 219 (44.4) 34 (53.1) .18
≥ 30 129 (21.2) 112 (22.8) 10 (15.9) .21
Mean FPG (mg/dL) 129.5 ± 58.2 127.21 ± 53.7 139.2 ± 75.6 .22
< 110 311 (52.2) 256 (52.7) 29 (45.3) .26
110 – 125 107 (18.0) 90 (18.6) 12 (18.7) .96
≥ 126 178 (30.0) 140 (28.8) 23 (36.0) .24
Total Cholesterol (mg/dL) 223.2 ± 47.7 222.9 ± 47. 6 221.7 ± 52.5 .85
Mean HDL (mg/dL) 37.4 ± 10.4 37.5 ± 10.6 36.5 ± 9.9 .49
Mean Triglycerides (mg/dL) 195.1 ± 121.0 193.7 ± 118.0 179.9 ± 97.0 .37
MS Components:
Obesity (BMI) 129 (21.2) 112 (22.7) 10 (15.6) .19
High Triglycerides 344 (57.1) 279 (57.1) 34 (53.1) .55
Low HDL-c 447 (78.1) 371 (79.3) 46 (75.4) .48
Hypertension 364 (59.6) 292 (59.1) 36 (55.4) .64
FPG ≥ 110 MG/dL 278 (46.6) 223 (45.9) 35 (54.7) .18
Table 2: Characteristics of the Vitoria general population
General rs7903146 p
CC + CT TT
Number of patients (%) 1577 (100) 1303 (89.9) 146 (10.0)
Male 718 (45.6) 600 (46.0) 64 (43.8) .61
Age (years) 44.8 ± 10.9 44.7 ± 10.9 44.3 ± 10.7 .65
Mean BMI (kg/m2) 26.3 ± 4.9 26.3 ± 5.0 26.2 ± 4.8 .82
< 25 692 (44.2) 573 (44.3) 65 (44.8) .91
25 – 29.9 513 (35.7) 458 (35.5) 55 (38.0) .54
≥ 30 285 (19.4) 260 (20.1) 25 (17.2) .41
Mean FPG (mg/dL) 105.01 ± 32 105.0 ± 32.3 105.7 ± 29.3 .82
< 110 1130 (78.7) 1014 (78.3) 116 (80.0) .64
110 – 125 241 (15.4) 200 (15.4) 22 (15.2) .93
≥ 126 123 (7.8) 102 (7.9) 14 (9.7) .45
Total Cholesterol (mg/dL) 214.4 ± 47.8 214.0 ± 48.1 215.4 ± 44.0 .74
Mean HDL (mg/dL) 45.4 ± 12.3 45.2 ± 12.1 44.0 ± 10.4 .27
Mean Triglycerides (mg/dL) 137.6 ± 127.9 137.2 ± 131.0 133.0 ± 82.1 .70
SBP (mmHg) 128 ± 2 128 ± 2 129 ± 2 .52
DBP (mmHg) 84 ± 1 84 ± 14 84 ± 14 .56
MS Components
Visceral obesity * 255 (16.2) 216 (16.6) 21 (14.4) .50
High triglycerides 484 (30.7) 391 (30.1) 51 (35.0) .23
Low HDL-c 848 (53.8) 705 (54.1) 79 (54.1) .99
Hypertension 727 (46.1) 596 (45.7) 75 (51.4) .19
FPG ≥ 110 MG/dL 334 (21.4) 281 (21.7) 29 (20.0) .63
Metabolic syndrome 397 (25.4) 326 (25.2) 40 (27.6) .53
*Abdominal circumference above cutoff points according to ATPIII criteria
BMC Medical Genetics 2008, 9:106 http://www.biomedcentral.com/1471-2350/9/106studied sample from the general population was only
24%.
Our previous risk model (Sousa AGP, unpublished
results) based solely on clinical criteria (age, presence of
hypertension and BMI) for predicting diabetes was able to
reach a good performance to identify individuals with an
increased likelihood of having diabetes. According to this
tool, individuals classified as having a higher probability
of becoming diabetic (higher score values) should be
assessed with further laboratorial tests for diabetes. Inter-
estingly, inclusion of the TT genotype in our model
resulted in no improvement on the area under the ROC
curve (AUC = 0.776; 95%CI 0.73–0.82 in both models).
The performance characteristics of two models (with only
demography variables and with TCF7L2 variables associ-
ated to demography variables) are shown in Table 5.
There was a slight improvement in specificity when the
TCF7L2 genotype TT was included, however the sensitivity
diminished. There was almost no difference among the
ROC curves of two models (Figure 1).
Although several studies have observed that the
rs7903146 SNP is associated with some of the metabolic
syndrome features, we did not observe any significant
association between the T risk allele and these characteris-
tics (Table 1 and 2).
Discussion
Recently Grant et al. [1] have described an association of
common genetic variants in TCF7L2 gene and type 2 dia-
betes risk, a finding which has been promptly replicated
in many populations worldwide and made this polymor-
phism one of the most important discoveries in the
pathophysiology of T2D in decades [20-22]. Initially, we
were able to confirm the association between polymor-
phism rs7903146 and T2D in a cohort of patients from
the MASS II protocol, whose diabetes prevalence was
31.1%. To our knowledge, this is the first study that con-
firmed this association in a South American population.
The odds ratio of association was similar to other previous
studies in different populations [1,2,6,15].
In the second stage, we have genotyped a large sample of
individuals from the general population of Brazil, which
has gone through intense admixing in its recent history
and is characterized by a genetic background that is
remarkably heterogeneous when compared to cohorts of
European or Asian ancestry. We genotyped a total of 1449
people looking for associations with diabetes and meta-
bolic syndrome components, which also have been asso-
ciated with this polymorphism in some, but not all,
studied populations [8,10]. Even though genotype fre-
quencies for the rs7903146 variants in our population
were somewhat similar to those reported previously in
different studies, we failed to confirm the association that
has been showing great consistency in case-control [23]
and general [11,24,25] populations all over the world. We
believe this finding is mostly due to the lack of statistical
power, because of the low diabetes prevalence and total
number of diabetic patients in the tested population than
Table 4: Logistic regression for type 2 diabetes risk
MASS II Vitoria
OR (95%CI) P value OR (95%CI) P value
T Allele 1.57 (1.18–2.19) 0.0025 1.15 (0.84–1.58) 0.391
Age 1.02 (0.99–1.04) 0.097 1.08 (1.06–1.10) < 0.0001
Female Sex 0.27 (0.02–3.11) 0.29 1.04 (0.69–1.59) 0.837
Obesity* 1.67 (1.08–2.56) 0.021 4.91 (3.25–7.43) < 0.0001
(*) BMI equal or greater to 30 kg/m2
Table 3: Genotype association with type 2 diabetes
rs7903146 DM n (%) Non-DM n (%) OR (95%CI) Allele test (P value‡)
MS2 CC 38 (22.0) 120 (31.1) 1.57 (1.16 – 2.11) 0.0032 (0.0034*)
CT 106 (61.3) 230 (59.6)
TT 29 (16.8) 36 (9.3)
VIT CC 45 (40.2) 564 (43.6) 1.126 (0.84–1.51) 0.426
CT 54 (48.2) 603 (46.6)
TT 13 (11.6) 128 (9.9)
(*) Adjusted for age and sex.
(‡) additive genetic modelPage 5 of 8
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genetic heterogeneity.
Most importantly, however, the addition of a known
TCF7L2 genotype in a validated model for predicting
prevalent diabetes was not able to improve the perform-
ance of the risk score: area under ROC curve in both mod-
els equal to 0.776, ie the inclusion of TCF7L2 genotype is
not better than the utilization of only clinical characteris-
tics to predict diabetes risk in our population. A very sim-
ilar result has been recently published by Balkau et al [26]
in an incidendt diabetes study in the French population.
The clinical and laboratorial prediction model improved
only modestly after inclusion of TCF7L2 and interleucin 6
(IL-6) SNPs information. Another example of a practical
consequence of applying the predictive model is the value
of Needing to Additional Tests (Table 5), which means the
proportion from population which would be tested for
T2D according to the model. It was observed only a little
difference in percentage of individuals that will be further
tested according to both models. In addition, as has been
demonstrated, the impact of most polymorphisms on
determining T2D risk is only modest. In order to improve
the accuracy of clinical predictors to assess diabetes risk in
a general population, it might be necessary to add several
genetic variants in the model [27,28]. Recent work from
ROC curves for the risk score in the two predictive modelsFigure 1
ROC curves for the risk score in the two predictive models. (*) p value for both models
Table 5: Performance of two predictive models in assessment T2D risk
Model 1 – Only Demography variables
Cutoffs Values Sensitivity Specificity PPV NPV Accuracy OR (95%CI) P value Needing to Additional Tests(%)
16.5 0.8426 0.6071 0.19 0.972 0.63 8.27 (3.86–12.68) < 0.00001 43.7
18 0.7037 0.7162 0.213 0.957 0.71 5.99 (3.38–8.60) < 0.00001 32.51
Model 2 – Demography and TCF7L2 TT Genotype variables
Cutoffs Values
16.5 0.8426 0.5939 0.185 0.972 0.62 7.83 (3.66–12.0) < 0.00001 44.89
18 0.7222 0.7081 0.213 0.959 0.71 6.30 (3.51–9.1) < 0.00001 33.42Page 6 of 8
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morphisms which have have been related to T2D and
tested them in a general population of elderly persons.
The prediction power is modestly enhanced when a
model with genetic information is compared to a clinical
characteristics model.
Finally, we also looked for a link between the rs7903146
variant of the TCF7L2 gene and features of the metabolic
syndrome such as weight, body mass index, hypertriglyc-
eridemia, hypertension, low HDL-c, as reported earlier
[8,18], but could not observe this even when data were
adjusted for age, race and abdominal circumpherence.
Conclusion
This finding adds to the importance of this polymorphism
in the pathogenesis of the disease and to the great consist-
ency in which data are replicated around the world. The
use of this particular genetic marker in stratifying individ-
uals regarding the risk of T2D appears to be dependent on
the a priori risk of the disease in the tested population.
One should exercise caution in the indiscriminate use of
genetic association results once the confirmation of the
biological association of a genetic marker with a common
chronic disease does not guarantee meaningful improve-
ment on already established screening tools based solely
on demographic variables.
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